The diagnostic value of serum chemerin/visfatin ratio for insulin resistance in PCOS patients.

Objective: To explore the level of the serum chemerin/visfatin ratio in patients with polycystic ovary syndrome (PCOS) and its diagnostic value for insulin resistance (IR). Methods: 264 PCOS patients admitted to the hospital from January 2022 to December 2024 were selected as the subjects. According to the steady-state model evaluation of insulin resistance index (HOMA-IR), the patients were divided into non IR group (HOMAIR < 2.69) and IR group (HOMA-IR ≥ 2.69). Clinical data, glucose-lipid metabolism parameters, sex hormone levels, and serum Chemerin and Visfatin levels were compared between the two patient groups. Multivariate logistic regression identified the risk factors for insulin resistance in PCOS patients. Receiver Operating Curve (ROC) is used to evaluate the value of relevant indicators for the occurrence of IR in PCOS patients. Results: A total of 152 patients developed IR in the hospital, with a detection rate of 57.58% in IR samples. According to HOMA-IR, patients were divided into non IR group (n = 112) and IR group (n = 152). The body mass index (BMI), alanine aminotransferase (ALT), serum creatinine (Scr), C-reactive protein (CRP), fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), luteinizing hormone (LH), and chemerin/visfatin levels in the IR group were higher than those in the non IR group, while follicle stimulating hormone (FSH) levels were lower than those in the non IR group (P < 0.05) logistic multiple regression analysis found that FBG, LH, chemerin/visfatin are risk factors for IR in PCOS patients, while FSH is a protective factor (P < 0.05) . ROC curve analysis showed that the AUC value of combined detection of FBG, FSH, LH, chemerin/visfatin in evaluating the occurrence of IR in PCOS patients was higher than that of single detection (Z = 3.923, 4.768, 4.193, 3.427, P < 0.05). Conclusion: chemerin/visfatin is closely related to the occurrence of insulin resistance in PCOS patients, and the combined use of FBG, FSH, and LH has high value in evaluating the occurrence of insulin resistance in PCOS patients. [ABSTRACT FROM AUTHOR]